Maureen O’Connell, Scholastic Incorporation

Maureen O’Connell

Exec. VP, CFO and CAO Scholastic Incorporation

Maureen O’Connell was appointed as Chief Finance Officer of Scholastic Corporation (NASDAQ: SCHL), on January, 2007. Scholastic is a global children’s books publishing, education and media company. O’Connell directly reports to the CEO, President and Chair of the Board – Mr. Richard Robinson.

O’Connell also serves as an Executive Vice President and Chief Administration Officer. In these roles, she overlooks the administrative and finance functions worldwide. She is responsible for Business Development, Scholastic Technology Services, Human Resources and Strategic Planning for global operations of Scholastic Incorporation. At Scholastic, she also served as Principal Accounting Officer from April 30, 2012 to August 20, 2012. She has served as O’Connell is a major in Accounting and Economics from the Stern School of Business at the NYU.

Prior to Scholastic, O’Connell has been instrumental in the various roles she played at major business houses. She started her career as a public accountant and became part of the publishing industry as the Director of Accounting at Primedia and successful moved up the corporate ladder thereon. She has served as a CFO in Barnes and Noble and later joined Gartner Inc. in September, 2002. At Gartner, she served as President and Chief Operating Officer, Executive Vice President and Chief Financial Officer and also served as the Chief Administrative Officer until October 2003. O’Connell was appointed as the Chief Financial Officer and Executive Vice President of Affinion Loyalty Group, Inc. since January 2, 2006 and served the positions at Trilegiant Corporation too. Prior to joining Scholastic Inc; O’Connell was a part of Affinion Publishing, LLC.

Ms. O'Connell is a Partner of New York at PrimeGenesis LLC. O’Connell is also on the Board of Directors for Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP). Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. O’Connell is a former member of the board of directors of Beazer Homes (NYSE: BZH), where she served as audit chair for most of her tenure.

© Garnet 2014 Theme by Addtwomore